Past year: ▼ 98%(0.01c – 7.00c USD)
Each one in plain English, with the numbers worked through for a shareholder.
27 June 2019material agreement● NeutralMajor
Took an exclusive licence to sell CB Scientific's Test4 cannabis test kits under its ProMED brand, paying a 30-40% royalty on every kit. The third deal announced in a month, and the only one with an actual product attached; six weeks later the company stopped filing altogether.
21 June 2019material agreement▼ BadMajor
Two weeks later, a second agreement-to-agree: 51% of Hemp Bloom LLC and its 600 acres in Colorado and Oregon, with the filing projecting $38 million of CBD or $182 million of CBG revenue by 2020 while conceding it might not be able to farm the land at all. Nothing further was ever filed about it.
20 June 2019quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported quarterly revenue of $0 and a net loss of $3 thousand for the period ended 2019-04-30.
19 June 2019quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported quarterly revenue of $0 and a net loss of $3 thousand for the period ended 2019-04-30.
14 June 2019late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
5 June 2019material agreement▼ BadMajor
Announced it had "agreed to come to a definitive agreement" to buy 51% of Hemp Sciences Corp for 60 million shares valued at six cents each, doubling the share count for a business that is a division of Nuvus Corp - one of the related parties that had been lending the company its operating cash. No definitive agreement or completion was ever filed.
1 May 2019late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its annual report would be filed late.
15 Mar 2019securities registration● Neutral
Apotheca Biosciences, Inc. amended a filing by which it registered a securities offering with the SEC.
19 Dec 2018quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported quarterly revenue of $0 and a net loss of $313 thousand for the period ended 2018-10-31.
17 Dec 2018late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
14 Dec 2018other material event● NeutralMajor
The Florida circuit court gave the company what it asked for: an order finding it was not and never had been a shell company, freeing shareholders to sell under Rule 144. The company's own history - incorporated to explore minerals, never mining, then licensing, then a reverse takeover - is exactly the shape the shell definition exists to catch.
6 Dec 2018securities registration● Neutral
Apotheca Biosciences, Inc. amended a filing by which it registered a securities offering with the SEC.
29 Nov 2018other material event● NeutralMajor
Sued in a Florida state court for a declaration that it had never been a "shell" company, after a broker's lawyer told shareholders it had been - which would block them from selling under Rule 144. A company asking a county court to settle a federal securities-law question about its own past.
5 Nov 2018securities registration● Neutral
Apotheca Biosciences, Inc. registered a securities offering with the SEC.
19 Sept 2018late filing notice▼ Bad
Apotheca Biosciences, Inc. amended its notice to the SEC that its quarterly report would be filed late.
14 Sept 2018late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
31 Aug 2018business combination● NeutralMajor
Filed the full disclosure record for the Apotheca takeover, which had actually closed on 6 March 2018 and been announced by press release in June - roughly six months before this filing. The company moved to St Petersburg, Florida, said it had no revenue and a going-concern problem, and disclosed that its cash had come from small related-party loans; chairman Sam Talari is described as holding about 68% of the votes.
20 June 2018quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported a quarterly net loss of $223 thousand for the period ended 2018-04-30.
15 June 2018late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
7 May 2018material agreement termination▼ BadMajor
Walked away from both Washington deals at once: the Affordable Green licence was settled and cancelled for 2.6 million restricted shares, and the Green Venture / MMS Farms letter of intent was terminated with nothing ever paid. Fourteen months and a string of small payments produced no business, and the shares came out of shareholders' pockets.
2 May 2018late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its annual report would be filed late.
9 Mar 2018business combination● NeutralMajor
Agreed to hand 60 million new shares - about 60% of the enlarged company - to the owners of a private Florida business called Apotheca Biosciences, which would take the board, the officers and the name. A reverse takeover: the Washington cannabis-licensing plan was being replaced wholesale by a CBD products venture.
18 Dec 2017auditor change▼ Bad
Dismissed auditor TAAD LLP, which had put a going-concern warning on both of the company's audited years because it needed money simply to service its debt. No replacement auditor was named in the filing.
18 Dec 2017late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
2 Nov 2017material agreement● NeutralMajor
Signed a second letter of intent, this time to take over Green Venture Capital's own letter of intent with MMS Farms, a licensed Washington marijuana grower, for $500,000 payable in instalments. A deal to buy a right to a deal - and still four months behind on the first licence it signed.
20 Sept 2017quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported quarterly revenue of $0 and a net loss of $20 thousand for the period ended 2017-07-31.
19 Sept 2017quarterly activities report▼ Bad
Apotheca Biosciences, Inc. reported quarterly revenue of $0 and a net loss of $20 thousand for the period ended 2017-07-31.
14 Sept 2017late filing notice▼ Bad
Apotheca Biosciences, Inc. notified the SEC that its quarterly report would be filed late.
7 Aug 2017material agreement▼ BadMajor
Chief executive Jason Sakowski bought 27 million restricted shares from the company's former directors and officers for a combined $15,000, taking control outright. Control of a listed company changed hands for the price of a used car, with payment not due until March 2018.
31 July 2017material agreement▼ BadMajor
Rewrote the Affordable Green licence again, raising the total owed to $2.3 million while the payment schedule showed what had actually been paid: $25,000, then $9,800, $15,200, $10,000 and $10,000. The company was meeting a multi-million-dollar commitment in five-figure instalments.
